Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

By C. Landen, A. Chávez-Reyes, C. Bucana, R. Schmandt, M. Deavers, Gabriel Lopez-Berestein, Anil Sood. Cancer Research, 2005

681 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

RNA interference in the clinic: challenges and future directions (2010, background): “These nanoliposomes are tenfold more effective in tissue delivery than DOTAP and have no identified toxicities to dat”
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma (2006, methodology): “To facilitate in vivo distribution, we incorporated the siRNA into a neutral liposome, DOP”
siRNA delivery systems for cancer treatment. (2009, background): “When siRNA was combined with paclitaxel, the therapy resulted in markedly reduced growth of ovarian cancers in themousemodel [52].”
Eph receptors and ephrins in cancer: bidirectional signaling and beyond (2010, background): “Downregulation of EPHA2 or EPHB4 by small interfering RNAs (siRNAs) or antisense oligonucleotides decreases cancer cell malignancy in culture and inhibits tumour growth in several mouse cancer model”